Better benefits start here

Prime integrates with health plans for total drug management — no matter where medicine happens or how it’s reimbursed. We’re member-centric, provider-aligned and data-driven. And we’re here to help make better, more affordable care easier for everyone.

Executive perspectives

At Prime, we’re focused on redefining our company and how we deliver integrated drug management to support the needs of clients and the members they serve. Dave Schlett, President, PBM Solutions, shares his thoughts about what we accomplished in 2022, and where we are headed in 2023.

Prime’s owner clients

Blue Cross and Blue Shield of Alabama

Blue Cross and Blue Shield of Kansas 

Blue Cross and Blue Shield of Minnesota 

Blue Cross and Blue Shield of Nebraska 

Blue Cross and Blue Shield of North Carolina

Blue Cross Blue Shield of North Dakota 

Blue Cross Blue Shield of Rhode Island

Blue Cross Blue Shield of Wyoming 

Capital BlueCross

Florida Blue 

Health Care Services Corporation (HCSC) 

Blue Cross and Blue Shield of Illinois
Blue Cross and Blue Shield of Texas
Blue Cross and Blue Shield of Oklahoma
Blue Cross and Blue Shield of New Mexico
Blue Cross and Blue Shield of Montana


Regence Health Plans

Regence Blue Shield Idaho
Regence Blue Cross Blue Shield of Oregon
Regence Blue Cross Blue Shield of Utah
Regence Blue Shield Washington

PRIME AND MAGELLAN RX

Joining forces for a brighter future

Prime Therapeutics closes $1.35 billion Magellan Rx acquisition, uniting pharmacy and medical drug management expertise. The combination creates an opportunity to transform the industry by driving affordability and integrating whole-person care to enhance the patient, provider and customer experience.

Consultant Leadership

ANN O’BRIEN

As Vice President of Consultant Relations at Prime Therapeutics (Prime), Ann O’Brien oversees consultant business strategy and creates opportunities for growth in the self-insured payor market.

JOE CHAMBERLIN

As Consultant Engagement Director at Prime Therapeutics (Prime), Joe Chamberlin is responsible for managing the relationships between Prime and its consultant partners.

OUR LEADERS

Our executive leadership team (ELT) develops Prime’s strategy and works to create the right conditions for employees to successfully execute on that strategy. They bring a deep understanding of the marketplace and dedication to Prime’s purpose to their important role in guiding both employees and clients toward success.

Driving greater use of biosimilars to help lower drug costs

As part of our total drug management strategy, we actively promote evidence-based use of biosimilars (and other low-cost drug options) that are endorsed by our Phamracy and Therapeutics Committee.

Employer groups

Our connected approach helps life be easier for employers. Members get the medicine they need to feel better and live well. Employers can choose products and services that help lower pharmacy benefit costs and improve health outcomes — with less disruption for employees.

Health plans

Created by health plans to be an integrated partner, that unique relationship gives us deeper access to the medical data to help close gaps in care and create an airtight seal on the pharmacy/medical connection. No other pharmacy benefit manager can offer Prime’s level of integration.

Our solutions

We take an integrated, channel-optimized, approach to design people-centered products that help manage cost and provide smarter care.

Our approach

We’re unlocking the potential of integrated drug management to help lower costs and deliver better outcomes.

Our story

Built on a unique business model we’ve become a leading integrated drug management company.

Related research

Perspectives

March 30, 2023

Drug oversupply, or stockpiling, due to overlapping drug refills can cause unnecessary drug costs

If you have a chronic condition, your pharmacy may notify you advance of…

Perspectives

March 28, 2023

Biosimilars are at the door, Part 3

News about biosimilars is everywhere. Sometimes you just need the basics. This four-part…

Perspectives

March 27, 2023

Specialty Drug Pipeline Update: March 2023

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…

B2B Marketing

Each Blue Cross® and/or Blue Shield® plan is an independent licensee of the Blue Cross and Blue Shield Association.